Skip to content

Assessment and Characterization of Sleep Among Video Game Adult Players Without Video Game Use Disorder : a Feasability Study

Assessment and Characterization of Sleep Among Video Game Adult Players Without Video Game Use Disorder : a Feasability Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07411404
Acronym
SLEEPLAY
Enrollment
40
Registered
2026-02-13
Start date
2025-12-01
Completion date
2027-09-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep, Video Gamers

Brief summary

The primary objective of the SLEEPLAY study is to assess the feasibility of a research protocol investigating the impact of video games on sleep in adults. More specifically, this study aims to identify potential barriers, facilitators of participation, and participant adherence to various measurement tools (such as actigraphy and melatonin assays) to validate the protocol for a larger future study. Additionally, it seeks to optimize the recruitment of regular adult gamers and determine the conditions that will enable better collection of objective sleep data. The relevance of this feasibility study lies in its ability to test and refine the methodology, thereby facilitating future research while minimizing costs and implementation time.

Interventions

BEHAVIORALSleep Assessment Protocol

Participants will engage in a structured protocol to assess sleep patterns and potential disturbances related to video game usage. This protocol includes: * Completion of diaries: Participants will maintain a sleep diary, video game usage diary, and screen time diary for 14 days to record their activities and sleep quality. * Clinical assessments: At Visit 2, participants will complete questionnaires related to sleep quality and disturbances, administered by a sleep specialist neurologist. * Actigraphy monitoring: Participants will wear an actimeter during the 14-day recording period to objectively measure sleep activity. * Biological sampling: After the 14 days, participants will provide urinary samples for analysis of 6-sulfatoxymelatonin to evaluate melatonin levels.

Sponsors

Centre Hospitalier Universitaire de Besancon
Lead SponsorOTHER
Association Le Don du Souffle
CollaboratorUNKNOWN

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Women and men aged 18 to 40 * Signed informed consent form * For regular gamers: playing video games at least 3 times a week in the past 2 years, with IGDT-10 (Ten-Item Internet Gaming Disorder Test) \> 5 * For control group: non-player or occasional player (at least once in the previous year, but less than once a month)

Exclusion criteria

* Night worker * WIth treatment for sleep disorder or interfering with melatonin secretion (betablokers, melatonin supplements,some antidepressants) * Any pathology leading to circadian rythm disorder, neurological or psychiatric disorder * major addiction (any game or gambling disorder) except for coffee and tabacco

Design outcomes

Primary

MeasureTime frameDescription
Recruitment CapacityMonth 20 of the studyNumber of participants successfully included in the study per month within each group (Regular Gamers and Non-Gamers).
Attrition rateMonth 21 at the end of the studyPercentage of participants who drop out of the study.
Data CompletenessMonth 21 at the end of the studyMean number of days with valid data for: sleep diary, video game and screen-use diary, actigraphy (≥90% wear time), urinary samples for 6-sulfatoxymelatonin
AcceptabilityMonth 20 of the studyProportion of subjects who accepted to participate in the study compared to the number of eligible patients contacted.

Secondary

MeasureTime frameDescription
Average Sleep Onset LatencyMonth 1Duration between going to bed and falling asleep, expressed in minutes (average calculated over 14 days)
Total Sleep Time (minutes) measured by wrist actigraphy.Up to Day 25 post-inclusionTotal nightly sleep duration estimated objectively using actigraphy.
Sleep Onset Latency (minutes) from daily sleep diary.Up to Day 25 post-inclusionTime between lying down and perceived sleep onset, self-reported each morning.
Sleep Efficiency (Actigraphy)Up to Day 25 post-inclusionSleep Efficiency (%) measured by actigraphy.
Circadian Phase Marker - 6-SMT AcrophaseUp to Day 25 post-inclusion6-sulfatoxymelatonin acrophase (clock time, hh:mm).
Pittsburgh Sleep Quality Index (PSQI)Up to Day 25 post-inclusionGlobal sleep quality score from the Pittsburgh Sleep Quality Index, ranging from 0 to 21; higher scores indicate poorer sleep quality (i.e. worse sleep quality)
Insomnia Severity Index (ISI)Up to Day 25 post-inclusionInsomnia severity index (ISI) total score, ranging from 0 to 28; higher scores indicate more severe insomnia symptoms (i.e.worse insomnia severity)
Morningness-Eveningness Questionnaire (MEQ)Up to Day 25 post-inclusionMorningness-Eveningness Questionnaire (MEQ) total score (self-reported measure, ranging from 16 to 86). Chronotype score; higher scores indicate stronger morningness preference.

Countries

France

Contacts

CONTACTKarine CHARRIERE, PhD
kcharriere@chu-besancon.fr+3367840302
PRINCIPAL_INVESTIGATORSilvio GALLI, MD

CHU de Besançon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026